In his first "Executive Decision" segment of Mad Money Monday evening, Jim Cramer spoke with David Ricks, chairman and CEO of Eli Lilly & Co. (LLY) , the drug maker whose shares fell 1.9% Monday, along with the broader markets, despite posting positive clinical trial data on the company's breast cancer therapy.
Ricks explained that Lilly's treatment, when added to the current standard of care, has shown to reduce the rate of breast cancer recurrence by 25%. He called the data "great news" for patients and their families, and called it the first significant advancement in almost 20 years.
Ricks also commented on the company's recent work creating neutralizing antibodies to treat Covid-19 patients. He said in just six months' time, they've gone from nothing to clinical trial data showing they can reduce hospitalization rates by as much as 72%. He said they continue to test their antibodies at hard-hit nursing homes and have partnered with Amgen Inc. (AMGN) to help with manufacturing.